Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Scientists at the McGovern Institute and the Broad Institute of MIT and Harvard have reengineered a compact RNA-guided enzyme ...

The only gene-editing therapy currently on the market is a CRISPR–Cas9-based treatment for two blood disorders, sickle-cell ...

The discovery of recombinant DNA proved that biology, not chemistry alone, could create new medicines like life-saving ...

Greetings and welcome to the PDS Biotech first quarter in 2025 earnings conference call. (operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to ...

A groundbreaking $44 million federal biotechnology grant that would have benefited several Birmingham institutions has been cancelled. The Birmingham Biotechnology Hub, led by Southern Research ...

Trust of our neighbors is increasingly required to our shared human experience.

Also lagging the market Wednesday are biotechnology shares, down on the day by about 2.6% as a group, led down by Allogene Therapeutics, trading lower by about 22.1% and Xilio Therapeutics ...

Danforth Technology Company launched Spearhead Bio to make the process of gene editing faster and more efficient.

Fidelity Select Biotechnology Portfolio earns an Average Process Pillar rating. The primary contributor to the rating is its parent firm's excellent long-term risk-adjusted performance ...